PL3484865T3 - Modulatory somatostatyny i ich zastosowania - Google Patents

Modulatory somatostatyny i ich zastosowania

Info

Publication number: PL3484865T3
Authority: PL; Poland
Prior art keywords: somatostatin modulators; somatostatin; modulators
Prior art date: 2016-07-14

Application number

PL17828375.0T

Other languages

English (en)

Inventor

Jian Zhao

Sangdon Han

Sun Hee Kim

Shimiao Wang

Yunfei Zhu

Original Assignee

Crinetics Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-14

Filing date

2017-07-12

Publication date

2023-01-09

2017-07-12 Application filed by Crinetics Pharmaceuticals, Inc. filed Critical Crinetics Pharmaceuticals, Inc.

2023-01-09 Publication of PL3484865T3 publication Critical patent/PL3484865T3/pl

Links

102000005157 Somatostatin Human genes 0.000 title 1
108010056088 Somatostatin Proteins 0.000 title 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
229960000553 somatostatin Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)

PL17828375.0T 2016-07-14 2017-07-12 Modulatory somatostatyny i ich zastosowania PL3484865T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662362493P	2016-07-14	2016-07-14
US201662411338P	2016-10-21	2016-10-21
PCT/US2017/041694 WO2018013676A1 (en)	2016-07-14	2017-07-12	Somatostatin modulators and uses thereof

Publications (1)

Publication Number	Publication Date
PL3484865T3 true PL3484865T3 (pl)	2023-01-09

Family

ID=60941935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17828375.0T PL3484865T3 (pl)	2016-07-14	2017-07-12	Modulatory somatostatyny i ich zastosowania

Country Status (24)

Country	Link
US (7)	US9896432B2 (pl)
EP (2)	EP3484865B1 (pl)
JP (2)	JP6967577B2 (pl)
KR (2)	KR20210134838A (pl)
CN (2)	CN109715612B (pl)
AU (2)	AU2017296392B2 (pl)
CA (1)	CA3030423A1 (pl)
DK (1)	DK3484865T3 (pl)
ES (1)	ES2931472T3 (pl)
HR (1)	HRP20221279T1 (pl)
HU (1)	HUE060182T2 (pl)
IL (1)	IL264178B2 (pl)
LT (1)	LT3484865T (pl)
MX (1)	MX390120B (pl)
NZ (1)	NZ750174A (pl)
PL (1)	PL3484865T3 (pl)
PT (1)	PT3484865T (pl)
RS (1)	RS63776B1 (pl)
SG (1)	SG11201900349VA (pl)
SM (1)	SMT202200465T1 (pl)
TW (1)	TWI789355B (pl)
UA (1)	UA125393C2 (pl)
WO (1)	WO2018013676A1 (pl)
ZA (1)	ZA201900317B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX390120B (es) *	2016-07-14	2025-03-20	Crinetics Pharmaceuticals Inc	Moduladores de la somatostatina y usos de los mismos.
EP3596062A4 (en) *	2017-03-16	2020-08-26	Crinetics Pharmaceuticals, Inc.	SOMATOSTATIN MODULATORS AND THEIR USES
EP3658560A4 (en)	2017-07-25	2021-01-06	Crinetics Pharmaceuticals, Inc.	SOMATOSTAT IN MODULATORS AND USES THEREOF
EP4092018A1 (en) *	2018-01-17	2022-11-23	Crinetics Pharmaceuticals, Inc.	Process of making somatostatin modulators
US11608335B2 (en)	2018-02-12	2023-03-21	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
US12172991B2 (en) *	2018-05-29	2024-12-24	Council Of Scientific & Industrial Research	Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
ES3022912T3 (en)	2018-09-18	2025-05-29	Crinetics Pharmaceuticals Inc	Somatostatin modulators and uses thereof
US20220267295A1 (en) *	2019-07-17	2022-08-25	Crinetics Pharmaceuticals, Inc.	Crystalline forms of somatostatin modulators
TWI841768B (zh)	2019-08-14	2024-05-11	美商克林提克斯醫藥股份有限公司	非肽生長抑制素(somatostatin)5型受體激動劑及其用途
MD4210700T2 (ro) *	2020-09-09	2025-11-30	Crinetics Pharmaceuticals Inc	Preparate ale unui modulator al somatostatinei
EP4294797A1 (en)	2021-02-17	2023-12-27	Crinetics Pharmaceuticals, Inc.	Crystalline forms of a somatostatin modulator
KR20240013126A (ko) *	2021-05-25	2024-01-30	크리네틱스 파마슈티칼스, 인크.	질환의 치료를 위한 소마토스타틴 조절제의 용도
CN117836340A (zh)	2021-09-28	2024-04-05	电化株式会社	氯丁二烯系嵌段共聚物、胶乳、胶乳组合物、以及橡胶组合物
TW202339747A (zh) *	2022-01-11	2023-10-16	美商克林提克斯醫藥股份有限公司	生長抑制素調節劑用於治療類癌症候群(carcinoid syndrome)之用途
CA3258700A1 (en)	2022-06-10	2023-12-14	Assia Chemical Industries Ltd.	SOLID FORMS OF PALTUSOTINE AND THEIR PREPARATION METHOD
CR20250214A (es) *	2022-10-28	2025-08-22	Basecamp Bio Inc	Agonistas del receptor 2 de somatostatina y sus usos
KR20250117433A (ko)	2022-12-13	2025-08-04	크리네틱스 파마슈티칼스, 인크.	소마토스타틴 아형-2 수용체(sst2r) 표적 치료제 및 이의 용도
KR20250162795A (ko)	2023-03-28	2025-11-19	크리네틱스 파마슈티칼스, 인크.	간 기능장애가 있는 환자에게 팔투소틴을 투여하기 위한 조성물 및 방법
WO2025111318A1 (en) *	2023-11-22	2025-05-30	Crinetics Pharmaceuticals, Inc.	Somatostatin subtype receptor 3 (sstr3) agonists and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1035154A (en)	1910-05-16	1912-08-13	Ernest G Clark	Machine for rectifying perforated music and masters.
FR2802206B1 (fr)	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP1451156A4 (en)	2001-11-27	2005-05-25	Merck & Co Inc	4-AMINOCHINOLINVERBINDUNGEN
PL372295A1 (pl) *	2002-02-04	2005-07-11	F.Hoffmann-La Roche Ag	Pochodne chinoliny jako antagoniści NPY
WO2005024416A1 (en)	2003-09-05	2005-03-17	Binghe Wang	Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
WO2006017326A1 (en) *	2004-07-13	2006-02-16	Glaxo Group Limited	Antibacterial agents
US20060183763A1 (en)	2004-12-31	2006-08-17	Pfizer Inc	Novel pyrrolidyl derivatives of heteroaromatic compounds
ES2391575T3 (es)	2005-12-05	2012-11-27	Xenoport, Inc.	Mesilato de profármaco de Levodopa, sus composiciones y sus usos
US20070265270A1 (en)	2006-02-21	2007-11-15	Hitchcock Stephen A	Cinnoline derivatives as phosphodiesterase 10 inhibitors
US20070299067A1 (en)	2006-03-08	2007-12-27	Ruiping Liu	Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
EP1996196A2 (en) *	2006-03-13	2008-12-03	Merck & Co., Inc.	Somatostatin agonists
US8735424B2 (en)	2008-09-02	2014-05-27	Novartis Ag	Bicyclic kinase inhibitors
GB0818241D0 (en) *	2008-10-06	2008-11-12	Cancer Res Technology	Compounds and their use
CA2806332C (en)	2010-07-30	2017-11-14	Oncotherapy Science, Inc.	Quinoline derivatives and melk inhibitors containing the same
BR112013030095A2 (pt)	2011-05-23	2019-09-24	Elan Pharm Inc	inibidores de atividade de lrrk2 cinase
US8871756B2 (en)	2011-08-11	2014-10-28	Hoffmann-La Roche Inc.	Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de)	2011-09-14	2013-03-14	Aicuris Gmbh & Co. Kg	Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
EP2763675A2 (en)	2011-10-05	2014-08-13	Mapi Pharma Limited	Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
JP6299591B2 (ja)	2012-07-03	2018-03-28	小野薬品工業株式会社	ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
PE20151203A1 (es) *	2012-10-16	2015-08-31	Janssen Pharmaceutica Nv	MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
SG11201602477YA (en) *	2013-09-30	2016-05-30	Ono Pharmaceutical Co	Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
TWI659021B (zh)	2013-10-10	2019-05-11	亞瑞克西斯製藥公司	Ｋｒａｓｇ１２ｃ之抑制劑
JPWO2015146929A1 (ja)	2014-03-24	2017-04-13	武田薬品工業株式会社	複素環化合物
US10011600B2 (en)	2014-09-25	2018-07-03	Araxes Pharma Llc	Methods and compositions for inhibition of Ras
HK1255074A1 (zh)	2015-07-01	2019-08-02	Crinetics Pharmaceuticals, Inc.	生长抑素调节剂及其用途
HK1255034A1 (zh)	2015-07-01	2019-08-02	Crinetics Pharmaceuticals, Inc.	生长抑素调节剂及其用途
SMT202400141T1 (it)	2015-12-17	2024-05-14	Merck Patent Gmbh	8-ciano-5-piperidino-chinoline come antagonisti di tlr7/8 e loro usi per trattamento di disturbi immunitari
JP6870082B2 (ja)	2016-07-07	2021-05-12	プランテックス・リミテッド	二メシル酸パルボシクリブの固体形態
MX390120B (es)	2016-07-14	2025-03-20	Crinetics Pharmaceuticals Inc	Moduladores de la somatostatina y usos de los mismos.
EP4092018A1 (en)	2018-01-17	2022-11-23	Crinetics Pharmaceuticals, Inc.	Process of making somatostatin modulators
ES3022912T3 (en)	2018-09-18	2025-05-29	Crinetics Pharmaceuticals Inc	Somatostatin modulators and uses thereof
US20220267295A1 (en)	2019-07-17	2022-08-25	Crinetics Pharmaceuticals, Inc.	Crystalline forms of somatostatin modulators
MD4210700T2 (ro)	2020-09-09	2025-11-30	Crinetics Pharmaceuticals Inc	Preparate ale unui modulator al somatostatinei

2017
- 2017-07-12 MX MX2019000588A patent/MX390120B/es unknown
- 2017-07-12 NZ NZ750174A patent/NZ750174A/en unknown
- 2017-07-12 HR HRP20221279TT patent/HRP20221279T1/hr unknown
- 2017-07-12 KR KR1020217035692A patent/KR20210134838A/ko not_active Ceased
- 2017-07-12 SM SM20220465T patent/SMT202200465T1/it unknown
- 2017-07-12 IL IL264178A patent/IL264178B2/en unknown
- 2017-07-12 JP JP2019500810A patent/JP6967577B2/ja active Active
- 2017-07-12 CN CN201780056677.9A patent/CN109715612B/zh active Active
- 2017-07-12 LT LTEPPCT/US2017/041694T patent/LT3484865T/lt unknown
- 2017-07-12 EP EP17828375.0A patent/EP3484865B1/en active Active
- 2017-07-12 UA UAA201901274A patent/UA125393C2/uk unknown
- 2017-07-12 AU AU2017296392A patent/AU2017296392B2/en active Active
- 2017-07-12 US US15/647,758 patent/US9896432B2/en active Active
- 2017-07-12 EP EP22194733.6A patent/EP4163276A1/en not_active Withdrawn
- 2017-07-12 PT PT178283750T patent/PT3484865T/pt unknown
- 2017-07-12 PL PL17828375.0T patent/PL3484865T3/pl unknown
- 2017-07-12 WO PCT/US2017/041694 patent/WO2018013676A1/en not_active Ceased
- 2017-07-12 SG SG11201900349VA patent/SG11201900349VA/en unknown
- 2017-07-12 CA CA3030423A patent/CA3030423A1/en active Pending
- 2017-07-12 CN CN202211105259.3A patent/CN115557929A/zh active Pending
- 2017-07-12 RS RS20221103A patent/RS63776B1/sr unknown
- 2017-07-12 ES ES17828375T patent/ES2931472T3/es active Active
- 2017-07-12 KR KR1020197004427A patent/KR102324042B1/ko active Active
- 2017-07-12 HU HUE17828375A patent/HUE060182T2/hu unknown
- 2017-07-12 DK DK17828375.0T patent/DK3484865T3/da active
- 2017-07-14 TW TW106123557A patent/TWI789355B/zh active
- 2017-12-20 US US15/849,409 patent/US10351547B2/en active Active
2019
- 2019-01-16 ZA ZA2019/00317A patent/ZA201900317B/en unknown
- 2019-05-08 US US16/407,031 patent/US10597377B2/en active Active
- 2019-12-12 US US16/712,620 patent/US10875839B2/en active Active
2020
- 2020-10-26 US US17/080,358 patent/US11414397B2/en active Active
- 2020-11-24 AU AU2020277122A patent/AU2020277122A1/en not_active Abandoned
2021
- 2021-10-22 JP JP2021173304A patent/JP2022028675A/ja not_active Ceased
2022
- 2022-07-01 US US17/810,497 patent/US20220380337A1/en not_active Abandoned
2025
- 2025-04-25 US US19/189,671 patent/US20260008767A1/en active Pending

Also Published As

Publication number	Publication date
SG11201900349VA (en)	2019-02-27
CN115557929A (zh)	2023-01-03
JP2022028675A (ja)	2022-02-16
ZA201900317B (en)	2022-10-26
JP6967577B2 (ja)	2021-11-17
IL264178B2 (en)	2024-05-01
MX390120B (es)	2025-03-20
HUE060182T2 (hu)	2023-02-28
EP4163276A1 (en)	2023-04-12
KR102324042B1 (ko)	2021-11-09
ES2931472T3 (es)	2022-12-29
US9896432B2 (en)	2018-02-20
NZ750174A (en)	2023-04-28
BR112019000692A2 (pt)	2019-04-24
US20180016252A1 (en)	2018-01-18
LT3484865T (lt)	2022-11-10
RS63776B1 (sr)	2022-12-30
AU2017296392B2 (en)	2020-09-24
CA3030423A1 (en)	2018-01-18
US20200190053A1 (en)	2020-06-18
CN109715612A (zh)	2019-05-03
TW201805276A (zh)	2018-02-16
US10351547B2 (en)	2019-07-16
EP3484865B1 (en)	2022-09-14
US10597377B2 (en)	2020-03-24
DK3484865T3 (da)	2022-10-31
SMT202200465T1 (it)	2023-01-13
US10875839B2 (en)	2020-12-29
KR20190026914A (ko)	2019-03-13
IL264178A (en)	2019-02-28
US20210171492A1 (en)	2021-06-10
US11414397B2 (en)	2022-08-16
HRP20221279T1 (hr)	2022-12-23
MX2019000588A (es)	2019-09-09
AU2017296392A1 (en)	2019-02-28
BR112019000692A8 (pt)	2022-03-03
IL264178B1 (en)	2024-01-01
CN109715612B (zh)	2022-09-16
US20220380337A1 (en)	2022-12-01
EP3484865A1 (en)	2019-05-22
US20190002431A1 (en)	2019-01-03
KR20210134838A (ko)	2021-11-10
JP2019520415A (ja)	2019-07-18
WO2018013676A1 (en)	2018-01-18
UA125393C2 (uk)	2022-03-02
US20260008767A1 (en)	2026-01-08
US20190382367A1 (en)	2019-12-19
AU2020277122A1 (en)	2020-12-24
PT3484865T (pt)	2022-11-03
TWI789355B (zh)	2023-01-11
EP3484865A4 (en)	2019-12-25

Publication	Publication Date	Title
ZA201900317B (en)	2022-10-26	Somatostatin modulators and uses thereof
IL275307B (en)	2022-03-01	Syntac polypeptides and their uses
IL269241A (en)	2019-11-28	Somatostatin modulators and their uses
IL273236A (en)	2020-04-30	Pyrazolopyrimidine compounds and their uses
IL265564A (en)	2019-05-30	Calpain modulators and their medical uses
IL247847B (en)	2020-09-30	ror gamma modulator and their use
EP3317277A4 (en)	2018-12-19	Somatostatin modulators and uses thereof
PL3853218T3 (pl)	2025-06-02	Modulatory somatostatyny i ich zastosowania
EP3317278A4 (en)	2018-12-05	Somatostatin modulators and uses thereof
ZA201801052B (en)	2021-05-26	Combinations and uses thereof
IL266261A (en)	2019-06-30	ror-gamma modulators
GB201616439D0 (en)	2016-11-09	Compounds and uses
IL264473A (en)	2019-02-28	GPR156 variants and their uses
ZA201905513B (en)	2020-05-27	Rorgamma modulators and uses thereof
GB201412821D0 (en)	2014-09-03	Polymeric proteins and uses thereof
IL254241A0 (en)	2017-10-31	Etv2 and its uses
GB201410031D0 (en)	2014-07-16	Polypeptides and uses thereof
ZA201905511B (en)	2020-05-27	Rorgamma modulators and uses thereof
IL273671A (en)	2020-05-31	Cornoline variants and their use
GB201614224D0 (en)	2016-10-05	Compounds and uses thereof
ZA201606656B (en)	2019-10-30	Ror-gamma modulators and uses thereof
GB201613143D0 (en)	2016-09-14	Polypeptides and uses thereof
GB201613142D0 (en)	2016-09-14	Polypeptides and uses thereof